{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreids6xlb6ubdwwdojg3qz6x2n4mjlrqzsmzdlr7ejwu3okhrx2v7d4",
    "uri": "at://did:plc:nnaxwirbqywidimahadp42bj/app.bsky.feed.post/3mntnivxnew62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie3x67go3zd37g7xrzekqgjciy6kbycrdih6v4ajd2lvenfqekgsu"
    },
    "mimeType": "image/jpeg",
    "size": 83716
  },
  "path": "/gsk-snaps-up-us-cancer-treatment-firm-nuvalent-in-10-6bn-deal/",
  "publishedAt": "2026-06-09T06:28:45.000Z",
  "site": "https://www.cityam.com",
  "tags": [
    "Business",
    "Markets",
    "Pharma",
    "Stock Market",
    "[...]"
  ],
  "textContent": "Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]",
  "title": "GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal"
}